Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial
Year: 2025
Type: article
Language: en
Topic: Advanced Breast Cancer Therapies
Authors and affiliations:
raw_author_name: Panagiotis A. Konstantinopoulos
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Panagiotis_konstantinopoulos@dfci.harvard.edu
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Ningxuan Zhou
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Richard T. Penson
raw_affiliation_strings: Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA
raw_author_name: Tien V. Le
raw_affiliation_strings: Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA
raw_author_name: Susana Campos
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Carolyn Krasner
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Alexi A. Wright
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Rebecca Porter
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Neil Horowitz
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Sara Bouberhan
raw_affiliation_strings: Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA
raw_author_name: Joyce F. Liu
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Sarah Hindenach
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Hannah Sawyer
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Lani Koppermann
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Martin Hayes
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Madeline Polak
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Meghan Shea
raw_affiliation_strings: Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
raw_author_name: Page Widick
raw_affiliation_strings: Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, 02215, USA
raw_author_name: Su-Chun Cheng
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Cesar Castro
raw_affiliation_strings: Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA
raw_author_name: Jan H. Beumer
raw_affiliation_strings: Department of Oncology, Johns Hopkins University School of Medicine and Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, USA
raw_author_name: Ursula A. Matulonis
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
raw_author_name: Elizabeth K. Lee
raw_affiliation_strings: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA